Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer

被引：0
|
作者：
Miano, S. T. [1 ]
Rossi, G. [1 ]
Marsili, S. [1 ]
Petrioli, R. [1 ]
Pascucci, A. [1 ]
Francini, G. [1 ]
机构：
[1] Uoc Oncol Med Scotte, Siena, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A67
引用
收藏
页码：22 / 23
页数：2
相关论文
共 50 条
  • [21] Treatment of HER2-negative metastatic breast cancer (MBC) with bevacizumab (BEV) plus paclitaxel (TXL): A singlecenter phase II study
    Inno, A.
    Strippoli, A.
    Nazzicone, G.
    Quaranta, A.
    Di Salvatore, M.
    Galiano, A.
    Bagala, C.
    Basso, M.
    Pozzo, C.
    Cassano, A.
    Astone, A.
    Barone, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Phase 1 Dose-Escalation Study of Triweekly Nab-Paclitaxel Combined With S-1 for HER2-Negative Metastatic Breast Cancer
    Morimoto, Masami
    Toba, Hiroaki
    Aoyama, Mariko
    Nakagawa, Misako
    Takechi, Hirokazu
    Yoshida, Takahiro
    Tangoku, Akira
    CLINICAL BREAST CANCER, 2020, 20 (06) : 448 - 453
  • [23] A pilot study of paclitaxel plus pembrolizumab in patients with metastatic HER2-negative breast cancer (PePPy)
    Tan, Antoinette R.
    Chai, S. Jean
    Robinson, Myra M.
    Hellner, Lane B.
    Gavini, Nagajyothi
    Sulai, Nanna
    Turner, J. David
    Atlas, Jennifer
    Graham, David L.
    Induru, Raghava R.
    Kadakia, Kunal C.
    Vallabhaneni, Geetha D.
    Heeke, Arielle L.
    Foureau, David M.
    Fisher, Julie G.
    CANCER RESEARCH, 2022, 82 (04)
  • [24] Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life
    De Luca, Rossella
    Profita, Giuseppe
    Cicero, Giuseppe
    ONCOTARGETS AND THERAPY, 2019, 12 : 1621 - 1627
  • [25] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
    Tiainen, Leena
    Tanner, Minna
    Lahdenpera, Outi
    Vihinen, Pia
    Jukkola, Arja
    Karihtala, Peeter
    Paunu, Niina
    Huttunen, Teppo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
  • [26] A randomized phase II study of nab-paclitaxel plus durvalumab plus neoantigen vaccine versus nab-paclitaxel plus durvalumab in metastatic triple-negative breast cancer (mTNBC).
    Hernandez-Aya, Leonel Fernando
    Gao, Feng
    Goedegebuure, Peter S.
    Ma, Cynthia X.
    Ademuyiwa, Foluso Olabisi
    Park, Haeseong
    Peterson, Lindsay Leuthen
    Bagegni, Nusayba Ali
    Bose, Ron
    Gillanders, William E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] SAFETY AND EFFICACY OF MAINTENANCE BEVACIZUMAB IN HER2-NEGATIVE METASTATIC BREAST CANCER
    Russillo, M.
    Metro, G.
    Giannarelli, D.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Cognetti, F.
    Fabi, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 105 - 105
  • [28] Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
    Sharma, Priyanka
    Abramson, Vandana G.
    O'Dea, Anne
    Nye, Lauren
    Mayer, Ingrid
    Pathak, Harsh B.
    Hoffmann, Marc
    Stecklein, Shane R.
    Elia, Manana
    Lewis, Sharon
    Scott, Jecinta
    De Jong, Jilliann A.
    Wang, Yen Y.
    Yoder, Rachel
    Schwensen, Kelsey
    Finke, Karissa
    Heldstab, Jaimie
    LaFaver, Stephanie
    Williamson, Stephen K.
    Phadnis, Milind A.
    Reed, Gregory A.
    Kimler, Bruce F.
    Khan, Qamar J.
    Godwin, Andrew K.
    CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3896 - 3904
  • [29] Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
    Palumbo, Raffaella
    Sottotetti, Federico
    Trifiro, Giuseppe
    Piazza, Elena
    Ferzi, Antonella
    Gambaro, Anna
    Spinapolice, Elena Giulia
    Pozzi, Emma
    Tagliaferri, Barbara
    Teragni, Cristina
    Bernardo, Antonio
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2189 - 2199
  • [30] Bevacizumab in the treatment of HER2-negative breast cancer
    Lorusso, Vito
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04) : 813 - 821
12345